Beta-Blockers
Definition
Beta-adrenergic receptor antagonists competitively block catecholamine binding at β1 (predominantly cardiac) and β2 (predominantly bronchial and vascular smooth muscle) receptors, reducing heart rate, contractility, conduction and renin release. The class is heterogeneous: members differ substantially in β1 selectivity, lipophilicity, intrinsic sympathomimetic activity, and whether they carry additional ion-channel effects. This page covers the class as a whole; the specific question of continuing or stopping therapy after myocardial infarction is on concepts/Beta-Blocker-Post-MI, and the class-III antiarrhythmic member is covered under concepts/Antiarrhythmic-Drugs.
Key Concepts
Mechanism and Selectivity
- β1 blockade slows sinus rate, reduces AV nodal conduction, decreases myocardial contractility and suppresses renin release — the basis of benefit in heart failure, ischaemia and rate control
- β2 blockade in the lung promotes bronchoconstriction, which is the mechanistic origin of the COPD safety question below
- Selectivity is relative and dose-dependent. So-called cardioselective agents lose β1 selectivity at higher doses, so the distinction matters most at low-to-moderate doses
- Bisoprolol has the highest β1:β2 selectivity in common use (~14:1), making it the preferred agent when bronchospasm is a concern (sources/bisoprolol-copd-jcopd-2023 — medium)
- Other class properties that distinguish members: lipophilicity (metoprolol and propranolol are lipophilic and cross the blood–brain barrier; atenolol and bisoprolol are hydrophilic), intrinsic sympathomimetic activity (partially antagonises resting bradycardia), and α-blockade (carvedilol) or nitric-oxide-mediated vasodilation (nebivolol)
- Sotalol is a hybrid: it has non-selective β-blocking activity plus class III potassium-channel blockade, so it sits in both this class and concepts/Antiarrhythmic-Drugs
Established Indications
- Heart failure with reduced ejection fraction (HFrEF): carvedilol, bisoprolol, metoprolol succinate and nebivolol have mortality benefit and are a cornerstone of guideline-directed therapy
- Post-myocardial infarction with reduced LVEF or heart failure: long-standing Class I therapy — see concepts/Beta-Blocker-Post-MI for the preservation-of-benefit question in patients without LV dysfunction
- Rate control in atrial fibrillation and suppression of ventricular arrhythmia, including as an adjunct in electrical storm
- Hypertension: no longer first-line for uncomplicated hypertension in most guidelines, though retained for specific compelling indications (post-MI, HFrEF, migraine, aortic disease)
- Aortic dissection, long QT syndromes (as adjunct), thyrotoxicosis, and perioperative use in selected patients
Where Class Benefit Is Now Questioned — Post-MI with Preserved EF
Detailed on concepts/Beta-Blocker-Post-MI; the class-level position is:
- REDUCE-AMI (n=5,020; LVEF ≥50%; metoprolol or bisoprolol vs none; median 3.5 years): death or new MI 7.9% vs 8.3% (HR 0.96; 95% CI 0.79–1.16; P=0.64), with no secondary endpoint favouring beta-blockade (sources/bb-mi-reduceami-nejm-2024 — very high)
- Preplanned individual-patient-level meta-analysis of five contemporary trials (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, CAPITAL-RCT; n=17,801; LVEF ≥50%) found no benefit on any endpoint (sources/bb-mi-nejm-2026 — very high)
- ABYSS (n=3,698; LVEF ≥40%; interruption vs continuation at a median 2.9 years post-MI): noninferiority not demonstrated — primary composite 23.8% vs 21.1% (HR 1.16; 95% CI 1.01–1.33; P=0.44 for noninferiority, upper CI exceeding the 3-percentage-point margin), driven entirely by cardiovascular hospitalisation while hard outcomes (death, MI, stroke) were virtually identical (sources/bb-mi-abyss-nejm-2024 — very high)
- SMART-DECISION (n=2,540; LVEF ≥40%, no HF, ≥1 year of prior therapy): discontinuation was noninferior — primary composite 7.2% vs 9.0% (HR 0.80; 95% CI 0.57–1.13; P=0.001 for noninferiority, upper bound below the 1.4 margin) (sources/BB-SMARTDECISION-NEJM-2026 — very high)
Respiratory Safety in COPD — the Class-Specific Controversy
- BLOCK COPD (n=532; moderate-to-severe COPD without an established beta-blocker indication; extended-release metoprolol vs placebo for ~1 year) was stopped early for futility and safety: metoprolol did not delay first exacerbation (202 vs 222 days; HR 1.05; P=0.66), was associated with more hospitalisation for exacerbation (HR 1.91) and numerically higher mortality (11 vs 5 deaths) (sources/metoprolol-block-copd-nejm-2019 — high)
- This directly contradicted prior observational studies and meta-analyses suggesting beta-blockers reduce exacerbation and death in COPD — now attributed to residual confounding and immortal time bias (sources/metoprolol-block-copd-nejm-2019 — high)
- A 35-RCT meta-analysis of bisoprolol in COPD (n=3,269) found the opposite direction: improved FEV1 (+0.46 L), FVC (+0.20 L), 6-minute walk distance, and reduced IL-6/IL-8/CRP, with no excess adverse events (RR 0.83; P=0.38) — and the authors concluded bisoprolol is safe and effective in COPD independent of cardiac comorbidity (sources/bisoprolol-copd-jcopd-2023 — medium)
- Practical implication: whether a beta-blocker is safe in COPD appears to depend on which beta-blocker and why it is being given. When there is a compelling cardiac indication the class is not withheld; the contested scenario is bronchospastic disease without a cardiac indication
Contradictions / Open Questions
- Metoprolol harms in COPD while bisoprolol appears to help — molecule, population, or method? BLOCK COPD (a randomised, placebo-controlled trial stopped for safety) found metoprolol increased exacerbation hospitalisation, whereas the bisoprolol meta-analysis found improved lung function and inflammatory markers. Three explanations are unresolved: (1) a genuine difference in β1 selectivity (bisoprolol ~14:1 vs metoprolol), (2) a population difference — BLOCK COPD enrolled patients with no cardiac indication while the meta-analysis pooled COPD+HF and COPD-alone subgroups through subgroup analysis rather than randomisation, or (3) a methods artefact, since the meta-analysis is dominated by unblinded Chinese RCTs with non-placebo controls and high heterogeneity (sources/metoprolol-block-copd-nejm-2019 — high; sources/bisoprolol-copd-jcopd-2023 — medium)
- The two discontinuation trials disagree on the soft endpoint. ABYSS failed noninferiority and SMART-DECISION achieved it; both are concordant on hard outcomes, and the divergence traces to cardiovascular hospitalisation — plausibly anti-anginal withdrawal effects or open-label detection bias rather than a true difference in ischaemic risk. Which design should govern practice is unsettled (sources/bb-mi-abyss-nejm-2024 — very high; sources/BB-SMARTDECISION-NEJM-2026 — very high)
- No trial has directly compared beta-blocker molecules for respiratory safety. The metoprolol-versus-bisoprolol question is being answered by inference across trials that differ in design, population and endpoint — a head-to-head comparison in bronchospastic disease does not exist (sources/bisoprolol-copd-jcopd-2023 — medium)
- Class-wide generalisation is unsafe. Because selectivity, lipophilicity and ancillary properties differ so much between members, evidence generated with metoprolol or bisoprolol should not automatically be extended to carvedilol, atenolol or nebivolol — a recurring problem in how this class is summarised and in how older trials are extrapolated (sources/bb-mi-nejm-2026 — very high)
Connections
- Related to concepts/Beta-Blocker-Post-MI — the continuation-versus-discontinuation question in patients without LV dysfunction
- Related to concepts/Antiarrhythmic-Drugs — sotalol bridges both classes; beta-blockers are adjunctive in electrical storm
- Related to entities/HFrEF — carvedilol, bisoprolol, metoprolol succinate and nebivolol have mortality benefit
- Related to entities/Atrial-Fibrillation — rate control and concomitant therapy
- Related to concepts/HF-COPD-Comorbidity — the respiratory-safety question in patients with both conditions
- Related to concepts/Cardiac-Resynchronization-Therapy — beta-blocker optimisation in device patients
- Related to entities/Acute-Coronary-Syndrome — secondary prevention context